Citation for published version (APA):
Taneike, M., Nishida, K., Omiya, S., Zarrinpashneh, E., Misaka, T., Kitazume-Taneike, R., ... Otsu, K. (2016). MTOR hyperactivation by ablation of tuberous sclerosis complex 2 in the mouse heart induces cardiac dysfunction with the increased number of small mitochondria mediated through the down-regulation of autophagy. *PLoS One*, *11*(3), [e0152628]. https://doi.org/10.1371/journal.pone.0152628

Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the Research Portal

Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
mTOR Hyperactivation by Ablation of Tuberous Sclerosis Complex 2 in the Mouse Heart Induces Cardiac Dysfunction with the Increased Number of Small Mitochondria Mediated through the Down-Regulation of Autophagy

Manabu Taneike1, Kazuhiko Nishida1, Shigemiki Omiya1, Elham Zarrinpashneh1, Tomofumi Misaka1, Rika Kitazume-Taneike1, Ruth Austin1, Minoru Takaoka1, Osamu Yamaguchi2, Michael J. Gambello3, Ajay M. Shah1, Kinya Otsu1*

1 Cardiovascular Division, King’s College London British Heart Foundation Centre of Excellence, London, United Kingdom, 2 Department of Cardiovascular Medicine, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan, 3 Division of Medical Genetics, Emory University School of Medicine, Atlanta, Georgia, United States of America

* kinya.otsu@kcl.ac.uk

Abstract

Mammalian target of rapamycin complex 1 (mTORC1) is a key regulator of cell growth, proliferation and metabolism. mTORC1 regulates protein synthesis positively and autophagy negatively. Autophagy is a major system to manage bulk degradation and recycling of cytoplasmic components and organelles. Tuberous sclerosis complex (TSC) 1 and 2 form a heterodimeric complex and inactivate Ras homolog enriched in brain, resulting in inhibition of mTORC1. Here, we investigated the effects of hyperactivation of mTORC1 on cardiac function and structure using cardiac-specific TSC2-deficient (TSC2-/-) mice. TSC2-/- mice were born normally at the expected Mendelian ratio. However, the median life span of TSC2-/- mice was approximately 10 months and significantly shorter than that of control mice. TSC2-/- mice showed cardiac dysfunction and cardiomyocyte hypertrophy without considerable fibrosis, cell infiltration or apoptotic cardiomyocyte death. Ultrastructural analysis of TSC2-/- hearts revealed misalignment, aggregation and a decrease in the size and an increase in the number of mitochondria, but the mitochondrial function was maintained. Autophagic flux was inhibited, while the phosphorylation level of S6 or eukaryotic initiation factor 4E -binding protein 1, downstream of mTORC1, was increased. The upregulation of autophagic flux by trehalose treatment attenuated the cardiac phenotypes such as cardiac dysfunction and structural abnormalities of mitochondria in TSC2-/- hearts. The results suggest that autophagy via the TSC2-mTORC1 signaling pathway plays an important role in maintenance of cardiac function and mitochondrial quantity and size in the heart and could be a therapeutic target to maintain mitochondrial homeostasis in failing hearts.
**Introduction**

Mammalian target of rapamycin complex 1 (mTORC1) plays a critical role in the regulation of cell growth, proliferation and metabolism [1]. mTORC1 positively controls protein synthesis by phosphorylating downstream substrates, namely eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) and p70 ribosomal S6 kinase 1 (S6K1). The phosphorylation of 4E-BP1 prevents its binding to eIF4E, enabling eIF4E to promote cap-dependent translation [2]. Active S6K1 phosphorylates several substrates, including S6, that function in translation initiation as well as other steps that drive protein production. In addition to protein synthesis, mTORC1 positively controls mitochondrial function through a yin yang 1-peroxisome proliferator activated receptor coactivator 1alpha (PGC-1alpha) transcriptional complex [3].

On the other hand, mTORC1 also plays an important role in protein degradation. In mammalian cells, there are two major systems of protein degradation, namely the ubiquitin/proteasome system and autophagy. mTORC1 inhibits autophagy [4] by phosphorylating unc-51 like autophagy activating kinase 1 (ULK1), a mammalian ortholog of Atg1 [5]. In autophagy, an isolation membrane sequesters a part of the cytoplasm or organelles including mitochondria to form an autophagosome [6]. The autophagosome fuses with a lysosome and becomes an autolysosome. Then, the materials contained in the autolysosome are degraded by lysosomal enzymes. Autophagy contributes to macromolecule synthesis and energy production as well as quality control of cytoplasmic proteins and organelles. We have previously reported that constitutive autophagy in the heart is a homeostatic mechanism for maintaining cardiomyocyte size, global cardiac structure and function and the quality of mitochondria [7].

Mitochondria are important organelles for ATP production and dynamic organelles. They continuously undergo fusion and fission during cell life, exhibiting short round-shaped or elongated morphology. Autophagy will be preceded by mitochondrial fission, which divides elongated mitochondria into pieces of manageable size for engulfment by isolation membrane. When autophagy is induced in the cells by nutrient depletion, mitochondria elongate [8]. Elongated mitochondria are spared from autophagy and maintain ATP production upon starvation.

mTORC1 is positively regulated by Ras homolog enriched in brain (Rheb). Rheb is a small GTPase, that exists either in an active GTP-bound or an inactive GDP-bound state [9]. In the signaling pathway towards mTORC1, tuberous sclerosis complex (TSC) 1 and 2 exist upstream of Rheb. Mutations in either the TSC1 or TSC2 gene are the principal cause of TSC, which is an autosomal dominant multisystemic disorder characterized by the development of numerous benign tumours (e.g. hamartomas) in many organs, such as brain, kidneys, skin, heart and lungs [10]. There is no homology between the 140 kDa TSC1 and the 200 kDa TSC2 proteins. TSC1 and TSC2 associate with each other to form a heterodimeric complex as a regulatory unit and a catalytic unit, respectively. The TSC1/2 complex is a GTPase-activating protein that catalyses the conversion of Rheb-GTP to Rheb-GDP [11] and inactivates Rheb, resulting in inhibition of mTORC1 signaling [12, 13]. Akt-mediated phosphorylation of TSC2 inhibits the function of the TSC1/2 complex [14], resulting in activation of mTORC1. However, the existence of an mTORC1-dependent feedback mechanism blocks growth-factor-stimulated phosphorylation of Akt [15].

Studies using *Drosophila* revealed that loss-of-function mutations of TSC1, TSC2 and both genes combined lead to organ overgrowth via increased cell proliferation and cell-autonomous increase in size [16, 17]. In mice, the deficiency of mTORC1 leads to embryonic lethality [18, 19]. Cardiac-specific mTOR-deficient mice are also embryonic lethal [20]. Furthermore, ablation of *Mtor* in the adult mouse heart results in a fatal, dilated cardiomyopathy, which is mainly
caused by enhanced dephosphorylation of 4E-BP1 [21]. These data suggest that mTOR has a critical role in protein synthesis to maintain cardiac function.

To investigate the role of the mTORC1 signaling pathway in the heart, mouse models where its activity is altered by modulation of upstream signaling molecules will be more physiologically relevant than Mtor ablation model. We previously investigated the role of mTORC1 in the heart using cardiac-specific Rheb-deficient mice, where mTORC1 was downregulated [22]. We found that mTORC1 activity through Rheb is essential for normal cardiac hypertrophic growth during the postnatal period, although autophagy was not related to the phenotypes observed in Rheb-deficient hearts. Since conventional TSC2-deficient mice are embryonic lethal [23, 24], we used cardiac-specific TSC2-deficient mice to examine the effect of mTORC1 hyperactivation on protein degradation and mitochondrial dynamics as well as protein synthesis in cardiomyocytes in this study. The ablation of TSC2 in mouse hearts leads to Rheb activation, mTORC1 activation, ULK1 phosphorylation and then finally inhibition of autophagy. Our results suggest that autophagy via the TSC-mTORC1 signaling pathway plays an important role in determining the size and number of mitochondria to maintain cardiac function.

Materials and Methods

Animals

All in vivo procedures in this study were carried out in accordance with the Guidance on the Operation of the Animals (Scientific Procedures) Act, 1986 (UK Home Office) or the Guidelines for Animal Experiments of Osaka University and the Japanese Act on Welfare and Management of Animals (No. 105). King’s College London Ethical Review Process Committee and UK Home Office (Project Licence No. PPL70/7260) or Osaka University Animal Experimentation Committee approved this study. Mortality was described as a possibility in the approved study protocols. Mice were given food and water ad libitum. Mice were monitored daily during the animal study including the survival study to minimize suffering. Animals that showed signs of significant clinical cardio-respiratory distress due to the development of heart failure (e.g., increased respiratory rates, reduced activity, piloerection, hunched posture) were immediately euthanized by CO2 exposure. In a small pilot study approved by Osaka University Animal Experimentation Committee and performed under the Guidelines for Animal Experiments of Osaka University and the Japanese Act on Welfare and Management of Animals (No. 105), 4 mice showed unexpected death (S1 Protocol). Autopsy of all the dead mice showed pleural effusion and increased lung weight, suggesting the cause of death was heart failure. Thus, euthanized mice were considered as deaths. All the mice were harvested in the early morning. We didn’t detect any difference in food consumption and body weight gaining among groups used in this study.

Generation of cardiac-specific TSC2-deficient mice and echocardiography

The generation of mice bearing a TSC2\textsuperscript{flox} allele, in which exon 2–4 of the TSC2 gene is flanked by two loxP sequences, has been previously reported [25]. Mice bearing the TSC2\textsuperscript{flox} allele were crossed with transgenic mice expressing Cre recombinase under the control of alpha-myosin heavy chain promoter (alpha-MyHC-Cre) [26]. The genetic backgrounds of the TSC2\textsuperscript{flox/flox} and alpha-MyHC-Cre mice are 129/SvJ x C57B/6J and C57B/6J, respectively. All mice which were used in this study were male. Vevo 2100 system with a 22–55-MHz linear transducer (Visual Sonics) was used to perform echocardiography on awake or anaesthetized mice. The echocardiography was performed on awake mice, those were trained prior to the actual
measurement. Isoflurane was used for echocardiography on anesthetized mice. The sonographer blinded to the groups. Trans-thoracic M-mode images were acquired in parasternal short axis view. Fractional shortening (FS) and end-diastolic left ventricular (LV) mass were calculated as $(100 \times (\text{end-diastolic LV internal dimension (LVIDd) — end-systolic LV internal dimension (LVIDs)})/\text{LVIDd})$ and $1.05 \times \left( (\text{LVIDd} + \text{end-diastolic interventricular septal thickness (IVSd)})^3 - \text{LVIDd}^3 \right)$, respectively.

Antibodies

Specific antibodies targeted to the following proteins were used for the Western blot analysis in 1,000 times dilution (except for the one to alpha-tubulin (3,000)) and according to manufacturers’ instructions: TSC1 (rabbit monoclonal, Cell Signaling Technology (CST), #6935), TSC2 (rabbit monoclonal, CST, #4308), phosphorylated Akt (rabbit monoclonal, CST, #4058), Akt (rabbit polyclonal, CST, #9272), phosphorylated AMP-activated protein kinase (AMPK) (rabbit monoclonal, CST, #2535), AMPK (rabbit polyclonal, CST, #2532), phosphorylated S6 (rabbit, polyclonal, CST, #2215), S6 (rabbit monoclonal, CST, #2217), ubiquitin (rabbit polyclonal, CST, #3933), microtubule-associated protein 1 light chain 3 (LC3) B (rabbit polyclonal, CST, #2775), alpha-tubulin (mouse monoclonal, CST, #3873), voltage-dependent anion channel (VDAC) (rabbit polyclonal, CST, #4866), Parkin (rabbit polyclonal, CST, #2132), 4E-BP1 (rabbit polyclonal, Abcam, ab2606), PINK1 (rabbit polyclonal, Abcam, ab23707), KDEL proteins (mouse monoclonal, Enzo Life Sciences, ADI-SPA-827), sequestosome 1/p62 (p62) (C-terminal specific) (guinea pig polyclonal, Progen, GP62-C), translocase of inner mitochondrial membrane 23 homolog (Timm23) (rabbit polyclonal, Proteintech, 11123-1-AP), 4-hydroxy-2-nonenal michael adducts (HNE) (rabbit polyclonal, Calbiochem, 393207). Tissues were lysed in homogenization buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2.5 mM Na-orthovanadate, 2.5 mM Na-pyrophosphate, 1 mM β-glycerophosphate, 1% Triton X-100) with protease inhibitors (PMSF or protease inhibitor cocktail (Sigma)). Western blots were incubated with the secondary antibodies, followed by developing with an infrared imaging system, ODYSSEY CLx (LI-COR). NIH Image J software (version 1.46r) or Image Studio software (LI-COR) was used to perform densitometric analyses.

Histological analysis

The heart was excised and immediately fixed in buffered 4% paraformaldehyde in PBS, embedded in paraffin, and sectioned to a thickness of 6 micrometers. Haematoxylin and eosin (H&E) staining was performed on serial sections. For wheat germ agglutinin (WGA) staining, heart samples were mounted and frozen in O.C.T. compound (Thermo Scientific), cryo-sectioned to a thickness of 6 micrometers and stained with FITC-conjugated lectin (Sigma) to measure cross sectional area of cardiomyocytes. To determine the number of cells undergoing nuclear fragmentation, TdT-mediated dUTP-biotin nick end labeling (TUNEL) assay was performed on paraffin-embedded heart sections, using In situ Apoptosis Detection Kit (Takara Bio Inc.). For electron microscopy, the heart was perfused and then fixed with 2% formaldehyde and 2% glutaraldehyde. LV tissues were processed for transmission electron microscopy. We measured the area of mitochondria or counted the number of mitochondria in micrographs taken at 10,000-fold magnification, using NIH Image J software (version 1.46r) for 4 fields per mouse.

Quantitative real-time RT-PCR

We isolated total RNA from the LV using the TRIzol reagent (Life Technologies). We determined mRNA expression levels for atrial natriuretic factor (Nppa), beta-myosin heavy chain (Myh7), collagen type 1 (Col1a2), Pgc-1a and Gapdh by quantitative RT-PCR. For reverse
transcription, we used SuperScript II Reverse Transcriptase (Life Technologies). Real-time PCR reaction was performed using Power SYBR Green Master Mix (Life Technologies) and PCR primers designed as follows: forward 5'-TCGTCTTGCCCTTTTGCT-3' and reverse 5'-TCCAGGTGTCAGCAGGTTCT-3' for Nppa, forward 5'-ATGTGCGGACCCTTGAAAG-3' and reverse 5'-CCTCAGGGTTAGGAGAGATA-3' for Myh7, forward 5'-ACGGCGGATCTGTTGCTGT-3' and reverse 5'-GGGGGCCCTTTTGCCAG-3' for Col1a2, forward 5'-AACAGACCTGACACAACGC-3' and reverse 5'-GTCATCTCAATTTCACCA-3' for Pgc-1a, forward 5'-ACGCGGACTCTGTTGCTGCT-3' and reverse 5'-TCAGGGACCCCTTTGTCCACG-3' for Gapdh. We constructed real-time PCR standard curves using the corresponding complementary DNA. All data were normalized to Gapdh content and are expressed as fold increase over the control group.

Mitochondrial enzyme activities

The activities of NADH cytochrome-c oxidoreductase (complex I + III) and succinate cytochrome-c oxidoreductase (complex II + III) were determined in mitochondrial fractions freshly isolated from hearts using previously described spectrophotometric methods [27]. Results are shown as nmol/min/mg protein.

Tissue ATP concentration and the ratio of ADP to ATP

The heart was excised and immediately frozen in liquid nitrogen. The samples were ground using a pestle and mortar chilled with liquid nitrogen. ATP concentration and the ratio of ADP to ATP were measured using EnzyLight ADP/ATP Ratio Assay Kit (BioAssay Systems).

Trehalose treatment

To examine the role of autophagy in the development of heart failure in TSC2⁻/⁻ mice, the mice were treated with 1% trehalose in drinking water for 10 weeks starting from 6 weeks after birth. The water solutions were changed twice weekly.

Statistical analysis

Results are shown as the mean ± S.E.M. Paired data were evaluated using a Student’s t-test. The Kaplan-Meier method with Logrank test was used for survival analysis. Distribution of mitochondrial size was analysed using Chi-square or Mann-Whitney U test. A value of P < 0.05 was considered statistically significant.

Results

Generation and characterization of mice lacking TSC2 in the heart

To investigate the effect of the upregulated mTORC1 signaling pathway in the heart, we generated cardiac-specific TSC2-deficient mice. TSC2floxflox mice were crossed with mice expressing alpha-myosin heavy chain promoter driven Cre recombinase (alpha-MyHC-Cre) to obtain TSC2floxflox, alpha-MyHC-Cre (TSC2⁻/-) mice. TSC2floxflox, alpha-MyHC-Cre (TSC2⁺/+), TSC2⁺/+ littermates were used as controls. The alpha-MyHC-Cre mice exhibited similar cardiac function to their control non-transgenic mice up to 12 months of age [28] and had normal life span. Western blot analysis revealed a 95% reduction of TSC2 protein in cardiomyocytes isolated from 8-week-old TSC2⁻/- hearts compared with those from TSC2⁺/+ hearts (Fig 1A). There was significant reduction in the expression level of TSC1 protein in TSC2⁻/- hearts. TSC1 and TSC2 associate with each other to form a heterodimer [29, 30]. Thus, there is a possibility that the stability of TSC1 is reduced by absence of TSC2. TSC2⁻/- mice were born normally at the
expected Mendelian ratio ($TSC2^{-/-}$:$TSC2^{+/+}$ = 38:43 delivered from crossing $TSC2^{-/-}$ with $TSC2^{+/+}$). However, $TSC2^{-/-}$ mice began to die at 4 months of age, and the median life span was approximately 10 months, which was significantly shorter than that of $TSC2^{+/+}$ mice (Fig 1B). The mortality at 4 months was 5%. Autopsy of dead mice showed pleural effusion and increased lung weight, suggesting the cause for death was heart failure. We evaluated physiological parameters in 4-month-old $TSC2^{-/-}$ mice (Fig 1C). There was no significant difference in body weight or the ratio of lung to body weight between $TSC2^{-/-}$ and $TSC2^{+/+}$ mice. The ratio of whole heart to body weight was significantly higher in $TSC2^{-/-}$ mice. Then, we performed trans-thoracic M-mode echocardiography on awake $TSC2^{-/-}$ mice to evaluate cardiac morphology and function (Fig 1D). Heart rate (HR), IVSd and LVPWd were significantly reduced and LVIDd and LVIDs were significantly increased in $TSC2^{-/-}$ mice compared with those in $TSC2^{+/+}$ mice. Furthermore, FS, an indicator of cardiac systolic function, was significantly lower and calculated LV mass was significantly increased in $TSC2^{-/-}$ mice compared with those in $TSC2^{+/+}$ mice. Since there was a possibility that reduced HR was the cause for reduction of systolic function in $TSC2^{-/-}$ mice, we performed echocardiography on anaesthetized mice to obtain the data under the same HR (S1 Fig). Under the situation, $TSC2^{-/-}$ mice showed increase in LV chamber size and decrease in LV contractility. Histological analysis by H&E staining indicated no significant fibrosis or cell infiltration (Fig 2A). WGA staining showed a significant increase in the cross-sectional area of cardiomyocytes in $TSC2^{-/-}$ mice.
compared with that in TSC2+/+ mice (Fig 2B and 2C). There was no significant difference in number of TUNEL-positive cardiomyocytes between the two groups (Fig 2E). Quantitative RT-PCR analyses showed higher mRNA expression levels of *Nppa* and *Myh7*, markers for cardiac remodeling, but not that of *Col1a2*, a marker for fibrosis, in TSC2−/− hearts (Fig 2G) in agreement with the histological analyses. These data indicate that TSC2−/− mice showed cardiomyocyte hypertrophy, LV chamber dilatation and cardiac dysfunction without considerable fibrosis, pulmonary congestion or apoptotic cardiomyocyte death at 4 months of age.

Biochemical features related to the mTORC1 signaling pathway in 4-month-old TSC2−/− mice

We examined the effect of TSC2 ablation on the mTORC1 signaling pathway in 4-month-old mouse hearts (Fig 3A). TSC1 was significantly decreased in TSC2−/− hearts although the difference was smaller compared to that in isolated cardiomyocytes. There were significant increases in the phosphorylation levels of S6 and 4E-BP1 in TSC2−/− hearts compared with TSC2+/+
hearts, indicating the activation of mTORC1 and resultant upregulation of protein synthesis in TSC2\textsuperscript{-/-} hearts. The phosphorylation level of Akt was significantly decreased in TSC2\textsuperscript{-/-} hearts compared with TSC2\textsuperscript{+/+} hearts, which is consistent with the existence of a negative feedback loop [31]. AMPK is a positive regulator of TSC2 protein, and its activation in response to a decrease in ATP and an increase in AMP in cytosol leads to TSC2 phosphorylation [1]. The phosphorylation level of AMPK was significantly decreased in TSC2\textsuperscript{-/-} group although the expression level of AMPK was increased. To evaluate the accumulation of ubiquitinated, misfolded or unnecessary proteins due to the excess of protein synthesis, we performed Western blot analyses for ubiquitin and KDEL proteins (GRP78 and GRP94), markers for endoplasmic...
reticulum stress (Fig 3B). However, we detected no significant differences in the expression levels of the proteins between the two groups. Since mTORC1 is known to be a negative regulator of autophagy in mammalian cells [4], we estimated the autophagic activity in TSC2−/− hearts (Fig 3C) [32]. The conversion of LC3-I to LC3-II is an essential step for autophagosome formation. The expression level of LC3-II was not significantly different between the two groups. However, p62, a marker for autophagic flux, was significantly accumulated in TSC2−/− hearts compared to TSC2+/+ hearts.

**Mitochondrial morphology in 4-month-old TSC2−/− hearts**

Mitochondria are the major source of energy production in cells and mTORC1 controls mitochondrial activity and biogenesis [33]. Therefore, we investigated the morphology of mitochondria using transmission electron microscopy. Ultrastructural analysis of TSC2−/− hearts showed misalignment, aggregation and a decrease in size of mitochondria (Fig 4A), but the intra-mitochondrial structure appeared to be maintained, as shown in the image insets. The frequency of smaller mitochondria was significantly increased in TSC2−/− hearts and the number of mitochondria per area was significantly bigger in TSC2−/− hearts compared with TSC2+/+ hearts (Fig 4B). Dysfunctional mitochondria generate reactive oxygen species. We estimated the amount of HNE proteins, which is a marker for oxidative stress, in the mitochondrial fraction (Fig 4C). The amount was significantly increased in TSC2−/− hearts, suggesting the accumulation of oxidative stress. However, PINK1 and Parkin, molecules related to mitophagy was decreased (Fig 4D) and total mitochondrial amount in the heart indicated by the levels of mitochondria-specific proteins, such as VDAC (a marker for outer membrane) and Timm23 (a marker for inner membrane) was not different between the two groups (Fig 4E).

**Protein synthesis and autophagic activities in 4-week-old TSC2−/− hearts**

To investigate the mechanism underlying cardiac dysfunction and mitochondrial morphologic changes in TSC2−/− mice, we examined cardiac phenotypes of the mice at an earlier time point, when the secondary effects caused by cardiac dysfunction were minimal. We selected 4 weeks of age to minimize the effects of rapid growth, although the mice had already showed cardiac dysfunction estimated by echocardiography on awake mice (Fig 1F). The wall thickness indicated by IVSd and LVPWd was not different between the two groups (Fig 1F) in contrast to the 4-month-old mice. The mortality at 4 weeks was 0% (Fig 1B). As we observed in 4-month-old TSC2−/− mice, HW/BW was increased (Fig 1E), CSA was increased (Fig 2D), apoptosis was not changed (Fig 2F), the expression level of Nppa was increased and that of Col1a2 was not changed (Fig 2H) in 4-week-old TSC2−/− mice. The expression level of Myh7 was not changed, while it was increased in 4-month-old TSC2−/− mice. These data suggest the progression of cardiomyopathy in TSC2−/− mice with time. In Western blot analysis, the phosphorylation level of Akt was significantly decreased and those of S6 and 4E-BP1 were significantly increased in the heart of TSC2−/− mice compared with those of TSC2+/+ mice (Fig 3D). There was no significant difference in the level of KDEL or ubiquitinated proteins (Fig 3E). These are the same changes as observed in 4-month-old TSC2−/− mice. In contrast to the 4-month-old hearts, the level of phosphorylated AMPK was significantly decreased in TSC2−/− hearts, and the expression level of TSC1 showed no significant difference (Fig 3D). The protein level of p62 was significantly increased in TSC2−/− hearts, as observed in 4-month-old TSC2−/− mice. The protein level of LC3-II was increased (Fig 3F), while that showed no significant increase in 4-month-old TSC2−/− mice. These suggest that the autophagic flux was attenuated due to impairment of autophagosome removal.
Ultrastructural analysis revealed a decrease in size and an increase in number of mitochondria in 4-week-old TSC2−/− hearts (Fig 4F and 4G), as observed in the 4-month-old hearts. As impaired mitochondrial function might be a cause for the cardiac dysfunction seen in TSC2−/− mice, we examined mitochondrial function by measuring respiratory chain enzyme activity in mitochondria isolated from mouse hearts (Fig 5A). However, there was no significant difference in the activity of either complex I + III or complex II + III between the two groups. We estimated the amount of HNE proteins in the mitochondrial fraction (Fig 4H). There was no significant difference in the protein level between the two groups, although that was increased
in 4-month-old TSC2−/− mice. The expression levels of PINK1 and Parkin were decreased (Fig 4I) as observed in 4-month-old TSC2−/− mice. Furthermore, we examined ATP concentration and the ratio of ADP to ATP concentration (ADP/ATP) in the heart tissue (Fig 5B). ATP concentration was found to be significantly increased in TSC2−/− hearts compared with TSC2+/+ hearts, and a significant decrease in ADP/ATP was detected. The mRNA expression of Pgc-1a measured by quantitative RT-PCR was preserved in TSC2−/− hearts (Fig 5C). These data indicate that the mitochondrial function was maintained in TSC2−/− hearts, although mitochondrial morphology was changed. Thus, the main cause of the cardiac phenotype seen in TSC2−/− hearts is not mitochondrial dysfunction.

Attenuation of the cardiac phenotypes in TSC2-deficient hearts by upregulation of autophagic flux

We hypothesized that reduced autophagic flux is one of the mechanisms for the cardiac phenotypes seen in TSC2−/− mice. To investigate the involvement of autophagy in cardiac phenotypes in TSC2−/− hearts, we treated the TSC2−/− mice with trehalose. Trehalose is a non-reducing disaccharide found in a wide variety of organisms, including bacteria, yeast, invertebrates, and plants and functions to protect cells against various environmental stresses [34]. Recently, it is reported that trehalose acts as an mTOR-independent autophagy activator and can reduce protein aggregates in some mouse disease models [35–37]. First, we treated TSC2+/+ mice with trehalose for 10 weeks starting from 6 weeks after birth to confirm upregulation of autophagic activity. Western blot analysis for LC3 indicated that autophagy was upregulated (Fig 6A). Thus, we treated TSC2−/− mice with trehalose for 10 weeks starting from 6 weeks after birth. After the treatment, cardiac function indicated by echocardiographic fractional shortening was significantly improved in the trehalose-treated group compared with control non-treated group (Fig 6B). The heart weight and the ratio of heart to body weight were not different between the two groups (Fig 6C). The accumulation of p62 was significantly reduced in trehalose-treated TSC2−/− hearts compared with control TSC2−/− hearts, although the protein level of...
LC3-II was not different (Fig 6D). This supports that trehalose increased autophagic flux in TSC2−/− mice. Ultrastructural analysis showed that the size of mitochondria was larger and the number was smaller in trehalose-treated group than those in control group (Fig 6E and 6F).

**Discussion**

In this study, we showed that the TSC-mTORC1 signaling pathway plays an important role to maintain cardiac function and to regulate mitochondrial size and number. Its homeostatic function is mediated through autophagy. Since mitochondria were not damaged in TSC2−/− hearts, autophagy is the main player in this system rather than mitochondria-specific autophagy, mitophagy.

It has been reported that cardiac-specific TSC1-deficient mice, which were generated by crossing floxed TSC1 mice with myosin light chain 2v-promotor driven Cre recombinase knock-in mice, had a median survival of 6 months and developed dilated cardiomyopathy [38]. Since TSC1 is required to stabilize TSC2 and prevents its ubiquitin-mediated degradation [29, 30], ablation of TSC1 would lead to downregulation of TSC2. It is reasonable that TSC1-deficient mice developed similar cardiac phenotypes to TSC2−/− mice. Thus, the TSC1/2 complex is essential for maintenance of cardiac function after birth, but not for heart development or...
survival during embryonic stage. Although the molecular mechanisms underlying the development of dilated cardiomyopathy in the TSC1-deficient mice have not been investigated, histological analysis of the mice showed the occurrence of scattered foci of enlarged cardiomyocytes accumulating glycogen without any evidence of proliferation in the lesion [38]. However, we did not observe such histological changes nor tumorigenesis in TSC2−/− hearts macroscopically and by echocardiography. Although the molecular mechanism underlying the difference in the histological findings between cardiac-specific TSC1 and TSC2-deficient hearts is unknown, it may be due to the timing of gene knockdown or distinct functions of the products of these genes.

TSC2 ablation in the heart led to not only cardiac dysfunction, but also a decrease in heart rate. ATP is released from cardiomyocytes [39, 40] and immediately metabolized to adenosine by ATPases that have their catalytic domain on the outer side of plasma membrane. Since adenosine is known to have a negative effect on heart rate [41], increased cytosolic ATP level may result in a decrease in heart rate in TSC2−/− mice. Other possibilities are that histological abnormalities including misalignment of mitochondria or direct effects of the TSC2 signaling pathway impair the function of the conduction system in the heart.

Autophagic flux indicated by protein level of LC3-II and p62 was decreased in TSC2−/− hearts at 4 weeks of age. Co-existence of increased LC3-II with increased p62 protein levels is consistent with impaired autophagosome removal rather than decreased formation. mTORC1 has been reported to regulate autophagy by signalling to ULK1 and lysosome homeostasis [5, 42].

We observed cardiomyocyte hypertrophy indicated by increases in heart-to-body weight ratio, LV mass and cross-sectional area of cardiomyocytes in TSC2−/− mice. Absence of fibrosis and cardiomyocyte death indicates that cardiac remodeling observed in TSC2−/− mice is not typical for general dilated cardiomyopathy. The hypertrophic responses can be induced by activation of protein synthesis. We previously reported that inhibition of autophagy in cardiomyocytes leads to cardiac hypertrophy [7]. In this study, as the treatment with trehalose had no effect on cardiac hypertrophy, the results suggest that inhibition of autophagy is not involved in the development of cardiac hypertrophy in TSC2−/− mice.

Our previous results showed that inhibition of autophagy in the heart by ablation of Atg5 induced misalignment and heterogeneous size of mitochondria and damage of intramitochondrial structure, impaired mitochondrial function and increased oxidative stress [7, 28]. If we consider the importance of autophagy for maintenance of normal functional mitochondria, it is surprising that TSC2−/− hearts showed normal mitochondrial respiratory function even with alteration in mitochondrial number and size. The normal mitochondrial function was confirmed by the results that ATP content was not decreased and oxidative stress was not increased in TSC2−/− hearts. This is in agreement with the previously reported in vitro studies that mitochondrial activity is stimulated and ATP levels are increased under the condition of constitutive mTORC1 activation in TSC2-deficient or knockdown cells [33, 43, 44]. The TSC2/mTORC1-dependent autophagy pathway may not be required for the removal of damaged mitochondria at least in the absence of TSC2. However, the mitochondrial function was measured using isolated mitochondria in this study and the assay has experimental limitation. It has been reported that isolation of mitochondria causes the difference in functional characteristics compared to intact mitochondria in permeabilized miofibers [45]. mTORC1 is reported to control mitochondrial ATP production capacity by selectively promoting translation of nucleus-encoded mitochondria-related mRNA [33]. Hyperactivation of mTORC1 may protect mitochondria against stress. We observed an increase in number and a decrease in size of mitochondria in TSC2−/− hearts. Consistent with our findings, the number of mitochondria is increased in pancreatic beta-cells lacking TSC2 [44]. The quantity, quality and size of
Mitochondria are determined by fusion and fission, followed by autophagy [46]. It is possible that the TSC2/mTORC1-dependent signaling pathway may be directly or indirectly involved in mitochondrial dynamics.

The activation of AMPK leads to TSC2 phosphorylation, resulting in restoration of ATP through regulation of metabolism and inhibition of growth via the mTORC1 pathway. AMPK phosphorylation was impaired in our TSC2-/- hearts, conversely the level was reported to be increased in tumor-derived cells or neurons lacking TSC2 [47, 48]. The phosphorylation level of AMPK in TSC2-/- hearts may be affected by the increase in intracellular ATP concentration. AMPK activates autophagy not only by inhibition of mTORC1 but also by direct phosphorylation of ULK1, which is required for autophagy induction [5, 48, 49]. In addition to activation of mTORC1 activity, inhibition of AMPK activity may suppress autophagic activity in TSC2-/- hearts. Although the decreased Akt phosphorylation level in TSC2-/- hearts can inhibit mTORC1 via proline-rich Akt substrate of 40 kDa (PRAS40), an endogenous mTORC1 inhibitor, the negative feedback mechanism would not be enough for the normalization of the mTORC1 signaling pathway.

mTORC1 positively regulates cell growth and proliferation by promoting biosynthesis of proteins and lipids and mitochondrial metabolism and biogenesis and also by limiting autophagy [1]. Over-activating these functions of mTORC1 could be related to the observed phenotypes in TSC2-/- hearts. mTOR controls mitochondrial oxidative function through a yin yang 1-PGC-1alpha transcriptional complex [3]. PGC-1alpha is known to promote mitochondrial biogenesis and function. In TSC2-/- hearts, mitochondrial function was maintained, ATP concentration was increased and the expression of PGC-1alpha was preserved. Therefore, we can exclude the possibility that impairment of mitochondrial metabolism and biogenesis is a cause for cardiac dysfunction in TSC2-/- mice.

We previously reported that inhibition of autophagy by cardiac-specific Atg5-deficient mice induces age-related cardiomyopathy [28] and it was found that the accumulation and aggregation of damaged or unnecessary proteins could cause the malfunction of biological processes and play an important role in aging. As signaling pathways towards protein synthesis were significantly accelerated in TSC2-/- hearts, there is a possibility that unnecessary or misfolded proteins were accumulated in cardiomyocytes to induce cardiac dysfunction. However, we observed no increase in ubiquitinated or KDEL proteins in TSC2-/- hearts. Some compensatory mechanisms, such as TSC2/mTORC1-independent autophagy, chaperone-mediated autophagy and proteasome system, could be involved in the maintenance of protein turnover. It is also possible that the ability of mTORC1-dependent autophagy still might be enough to respond to the increased protein load.

PINK1 and Parkin are known to be key molecules for damaged mitochondria clearance via ubiquitination and mitophagy in neuron [50]. Surprisingly, the expression level of PINK1 and Parkin was reduced in TSC2-/- hearts, suggesting PINK1 and Parkin-related mitophagy is down-regulated. Although it was reported that suppression of mTOR pathway can increase the expression level of PINK1 and Parkin [51], it is unclear why PINK1 and Parkin are reduced in this model. Further study is requested to clarify the effect of the decreases in PINK1/Parkin levels on the cardiac phenotype and mitochondrial morphology observed in TSC2-/- mice.

The protein level of p62 was significantly decreased by treatment of trehalose for 10 weeks, suggesting that autophagic flux was improved by trehalose treatment. However, the protein level of LC3-II was not different between control and trehalose-treated TSC2-/- groups. This might be due to the balance between the upregulation of autophagic induction and autolysosomal removal. The protective effect of trehalose on cardiac dysfunction in TSC2-/- mice indicates the existence of an mTOR-independent pathway to enhance autophagic flux. Upregulation of autophagic activity by trehalose treatment improved the cardiac function, indicating that
downregulation of autophagy could be a significant cause for cardiac phenotypes in TSC2−/− mice. Since the extent of rescue of the cardiac phenotypes was partial, we could not exclude possibilities that mechanisms other than autophagy are involved in the development of cardiac phenotypes in TSC2−/− mice. Trehalose is not a selective activator of autophagy [34]. Furthermore, trehalose does not appear to be absorbed and is rather broken down to glucose in the gastrointestinal tract of mammals [52]. Thus, we cannot exclude a possibility that improvement in cardiac function is due to the other potential "off-target" effects of trehalose. Molecular mechanisms how downregulation of autophagic flux in TSC2−/− mice resulted in the impairment of cardiac function remain to be elucidated. Cytoarchitectural disorganization would lead to cardiac dysfunction [53]. Ultrastructural images of TSC2−/− hearts showed misalignment of mitochondria and looked as if many of mitochondria could not interact with myofibril closely, suggesting that energy transfer between mitochondria and myosin-ATPase could be restricted. Activated autophagy can remove not only small mitochondria but also other cytoplasmic components and improve the interaction and energy transfer between mitochondria and myofibril. It is also possible that the misaligned mitochondria simply disturb sarcomere contraction.

In conclusion, we demonstrated that constitutive stimulation of mTORC1 signaling by TSC2 ablation in the heart leads to cardiac chamber dilatation and dysfunction and that upregulation of autophagic activity attenuates the cardiac dysfunction. Autophagy regulated by TSC-mTORC1 signaling in the heart is essential for the control of mitochondrial quantity. It is reported that mTORC1 inhibitors such as rapamycin can be pharmacological treatments of TSC disease [54, 55]. Trehalose could be a novel therapeutic for TSC patients. However, further investigation is required to reveal the involvement of autophagy in the pathogenesis of the disease with benign tumours.

Supporting Information
S1 Fig. Echocardiographic analysis of the mice at 4 months of age under anaesthesia. (PDF)
S2 Fig. The original blots shown in Figs 1, 3, 4 and 6. (PDF)
S1 Protocol. Methods for the pilot study. (DOCX)

Acknowledgments
We thank Dr. Gema Vizcay-Barrena, Centre for Ultrastructural Imaging at King’s College London for processing the samples for transmission electron microscopy.

Author Contributions
Conceived and designed the experiments: KO. Performed the experiments: M. Taneike KN SO EZ TM RKT RA M. Takaoka. Analyzed the data: M. Taneike KN SO EZ TM RKT RA M. Takaoka OY. Contributed reagents/materials/analysis tools: MJG. Wrote the paper: M. Taneike KN MJG AMS KO.

References
1. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci. 2009; 122(Pt 20):3589–94. doi: 10.1242/jcs.051011 PMID: 19812904
2. Richter JD, Sonenberg N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature. 2005; 433(7025):477–80. PMID:15690031

3. Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature. 2007; 450 (7170):736–40. PMID:18046414

4. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem. 2009; 284 (12):8023–32. doi: 10.1074/jbc.M900301200 PMID:19150980

5. Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011; 13(2):132–41. doi: 10.1038/ncb2152 PMID:22078875

6. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell. 2011; 147(4):728–41. doi:10.1016/j.cell.2011.10.026 PMID: 22078875

7. Nakai A, Yamaguchi O, Takeda T, Higuchi Y, Hikoso S, Tanike M, et al. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med. 2007; 13(5):619–24. PMID: 17450150

8. Gomes LC, Di Benedetto G, Scorrano L. During autophagy mitochondria elongate, are spared from degradation and sustain cell viability. Nat Cell Biol. 2011; 13(5):589–98. doi:10.1038/ncb2220 PMID: 21478857

9. Yamagata K, Sanders LM, Kaufmann WE, Yee W, Barnes CA, Nathans D, et al. Rheb, a growth factor- and synaptic activity-regulated gene, encodes a novel Ras-related protein. J Biol Chem. 1994; 269 (23):16333–9. PMID:8206940

10. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J. 2008; 412(2):179–90. doi: 10.1042/BJ20080281 PMID: 18466115

11. Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003; 17(15):1829–34. PMID:12869586

12. Tabancay AP Jr., Gau CL, Machado IM, Uhlmann EJ, Gutmann DH, Guo L, et al. Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K. J Biol Chem. 2003; 278(41):39921–30. PMID:12869548

13. Tee AR, Blenis J, Proud CG. Analysis of mTOR signaling by the small G-proteins, Rheb and RhebL1. FEBS Lett. 2005; 579(21):4763–8. PMID:16098514

14. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002; 4(9):648–57. PMID:12172553

15. Manning BD. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol. 2004; 167(4):399–403. PMID: 15533996

16. Tapon N, Ito N, Dickson BJ, Treisman JE, Hariharan IK. The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell. 2001; 105(3):345–55. PMID: 11348591

17. Potter CJ, Huang H, Xu T. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell. 2001; 105(3):357–68. PMID:11348592

18. Gangloff YG, Mueller M, Dann SG, Svoboda P, Sticker M, Spetz JF, et al. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol Cell Biol. 2004; 24(21):9508–16. PMID: 15485918

19. Murakami M, Ichisaka T, Maeda M, Oshiro N, Hara K, Denenhofer F, et al. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cell development. Mol Cell Biol. 2004; 24(15):6710–8. PMID: 15254238

20. Zhu Y, Pires KM, Whitehead KJ, Olsen CD, Wayment B, Zhang YC, et al. Mechanistic target of rapamycin (Mtor) is essential for murine embryonic heart development and growth. PLoS One. 2013; 8(1):e54221. doi: 10.1371/journal.pone.0054221 PMID: 23342106

21. Zhang D, Contu R, Latronico MV, Zhang J, Rizzii R, Catalucci D, et al. MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. J Clin Invest. 2010; 120(8):2805–16. doi: 10.1172/JCI43008 PMID: 20642457

22. Tamai T, Yamaguchi O, Hikoso S, Takeda T, Tanike M, Oka T, et al. Rheb (Ras homologue enriched in brain)-dependent mammalian target of rapamycin complex 1 (mTORC1) activation becomes indispensable for cardiac hypertrophic growth after early postnatal period. J Biol Chem. 2013; 288 (14):10716–87. doi: 10.1074/jbc.M112.423640 PMID: 23426372

23. Kobayashi T, Minowa O, Kuno J, Mitani H, Hino O, Noda T. Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res. 1999; 59 (6):1206–11. PMID: 10096549
24. Onda H, Lueck A, Marks PW, Warren HB, Kwiatkowski DJ. Tsc2(+/−) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J Clin Invest. 1999; 104(6):687–95. PMID:10491404

25. Hernandez O, Way S, McKenna J 3rd, Gambello MJ. Generation of a conditional disruption of the Tsc2 gene. Genesis. 2007; 45(2):101–6. PMID:17245776

26. Yamaguchi O, Watanabe T, Nishida K, Kashiwase K, Higuchi Y, Takeda T, et al. Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J Clin Invest. 2004; 114(7):937–43. PMID:15467832

27. Trounce IA, Kim YL, Jun AS, Wallace DC. Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines. Methods Enzymol. 1996; 264:484–509. PMID:8965721

28. Taneike M, Yamaguchi O, Nakai A, Hikoso S, Takeda T, Mizote I, et al. Inhibition of autophagy in the heart induces age-related cardiomyopathy. Autophagy. 2010; 6(5):600–6. doi:10.4161/auto.6.5.11947 PMID:20431347

29. Benvenuto G, Li S, Brown SJ, Braverman R, Vass WC, Cheadle JP, et al. The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene. 2000; 19(54):6306–16. PMID:11175345

30. Chong-Kopera H, Inoki K, Li Y, Zhu T, Garcia-Gonzalo FR, Rosa JL, et al. TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase. J Biol Chem. 2006; 281(13):8313–6. PMID:16464865

31. Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N, et al. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest. 2003; 112(8):1223–33. PMID:14567832

32. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012; 8(4):445–544. PMID:22966490

33. Morita M, Gravel SP, Chenard V, Sikstrom K, Zheng L, Alain T, et al. mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab. 2013; 18(5):698–711. doi: 10.1016/j.cmet.2013.10.001 PMID:24206664

34. Chen Q, Haddad GG. Role of trehalose phosphate synthase and trehalose during hypoxia: from flies to mammals. J Exp Biol. 2004; 207(Pt 18):3125–9. PMID:15299033

35. Davies JE, Sarkar S, Rubinsztein DC. Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy. Hum Mol Genet. 2005; 14(3):429–35. PMID:15601645

36. Rodriguez-Navarro JA, Rodriguez L, Casarejos MJ, Solano RM, Gomez A, Peruccho J, et al. Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation. Neurobiol Dis. 2010; 39(3):243–38. doi: 10.1016/j.nbd.2010.05.014 PMID:20546895

37. Schaeffer V, Lavenir I, Ozcelik S, Tolnay M, Winkler DT, Goedert M. Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy. Brain. 2012; 135(Pt 7):2169–77. doi: 10.1093/brain/aws143 PMID:22689910

38. Meikle L, McMullen JR, Sherwood MC, Lader AS, Walker V, Chan JA, et al. A mouse model of cardiac rhabdomyoma generated by loss of Tsc1 in ventricular myocytes. Hum Mol Genet. 2005; 14(3):429–35. PMID:15601645

39. Kunugi S, Iwabuchi S, Matsuyama D, Okajima T, Kawahara K. Negative-feedback regulation of ATP release: ATP release from cardiomyocytes is strictly regulated during ischemia. Biochem Biophys Res Commun. 2011; 416(3–4):409–15. doi: 10.1016/j.bbrc.2011.11.068 PMID:22133679

40. Dutta AK, Sabirov RZ, Uramoto H, Okada Y. Role of ATP-conductive anion channel in ATP release from neonatal rat cardiomyocytes in ischaemic or hypoxic conditions. J Physiol. 2004; 559(Pt 3):799–812. PMID:15272030

41. Froldi G, Belardinelli L. Species-dependent effects of adenosine on heart rate and atrioventricular nodal conduction. Mechanism and physiological implications. Circ Res. 1990; 67(4):960–78. PMID:2208618

42. Rocznik-Ferguson A, Petit CS, Froehlich F, Qian S, Ky J, Angarola B, et al. The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis. Sci Signal. 2012; 5(228):ra42. doi: 10.1126/scisignal.2002790 PMID:22692423

43. Schieke SM, Phillips D, McCoy JP Jr., Aponte AM, Shen RF, Balaban RS, et al. The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J Biol Chem. 2006; 281(37):27643–52. PMID:16847060
44. Koyanagi M, Asahara S, Matsuda T, Hashimoto N, Shigeyama Y, Shibutani Y, et al. Ablation of TSC2 enhances insulin secretion by increasing the number of mitochondria through activation of mTORC1. PLoS One. 2011; 6(8):e23238. doi:10.1371/journal.pone.0023238 PMID: 21886784

45. Picard M, Taivassalo T, Ritchie D, Wright KJ, Thomas MM, Romestaing C, et al. Mitochondrial structure and function are disrupted by standard isolation methods. PLoS One. 2011; 6(3):e18317. doi:10.1371/journal.pone.0018317 PMID: 21512578

46. Youle RJ, van der Bliek AM. Mitochondrial fission, fusion, and stress. Science. 2012; 337(6098):1062–5. doi:10.1126/science.1219855 PMID: 22936770

47. Lacher MD, Pincheira R, Zhu Z, Camoretti-Mercado B, Matli M, Warren RS, et al. Rheb activates AMPK and reduces p27Kip1 levels in Tsc2-null cells via mTORC1-independent mechanisms: implications for cell proliferation and tumorigenesis. Oncogene. 2010; 29(50):6543–56. doi:10.1038/onc.2010.393 PMID: 20818424

48. Di Nardo A, Wertz MH, Kwiatkowski E, Tsai PT, Leech JD, Greene-Colozzi E, et al. Neuronal Tsc1/2 complex controls autophagy through AMPK-dependent regulation of ULK1. Hum Mol Genet. 2014; 23(14):3865–74. doi:10.1093/hmg/ddu101 PMID: 24599401

49. Egan DF, Shackelford DB, Mihaylova MM, Gelino S, Kohnz RA, Mair W, et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science. 2011; 331(6016):456–61. doi:10.1126/science.1196371 PMID: 21205641

50. Youle RJ, Narendra DP. Mechanisms of mitophagy. Nat Rev Mol Cell Biol. 2011; 12(1):9–14. doi:10.1038/nrm3028 PMID: 21179058

51. Klinkenberg M, Gispert S, Dominguez-Bautista JA, Braun I, Auburger G, Jendrach M. Restriction of trophic factors and nutrients induces PARKIN expression. Neurogenetics. 2012; 13(1):9–21. doi:10.1007/s10048-011-0303-8 PMID: 22028146

52. Ishihara R, Taketani S, Sasai-Takedatsu M, Kino M, Tokunaga R, Kobayashi Y. Molecular cloning, sequencing and expression of cDNA encoding human trehalase. Gene. 1997; 202(1–2):69–74. PMID: 9427547

53. Joubert F, Wilding JR, Fortin D, Domergue-Dupont V, Novotova M, Ventura-Clapier R, et al. Local energetic regulation of sarcoplasmic and myosin ATPase is differently impaired in rats with heart failure. J Physiol. 2008; 586(Pt 21):5181–92.

54. Kenerson H, Dundon TA, Yeung RS. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res. 2005; 57(1):67–75. PMID: 15557109

55. Sato A, Kasai S, Kobayashi T, Takamatsu Y, Hino O, Ikeda K, et al. Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex. Nat Commun. 2012; 3:1292. doi:10.1038/ncomms2295 PMID: 23250422